Japan-based Eisai and Biogen have reported positive topline results from the Phase II Study 201 trial of BAN2401 for the treatment of early Alzheimer’s disease (AD).

Study 201 enrolled 856 patients with mild cognitive impairment (MCI) due to AD or mild Alzheimer’s dementia, both of which are collectively known as early Alzheimer’s disease, with confirmed amyloid pathology in the brain.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The placebo-controlled, double-blind, parallel-group, randomised trial examined the efficacy of BAN2401 at 18 months by predefined conventional statistics on Alzheimer’s Disease Composite Score (ADCOMS).

As part of the trial, patients were randomised to receive five dose regimens, including 2.5mg/kg biweekly, 5mg/kg monthly, 5mg/kg biweekly, 10mg/kg monthly and 10mg/kg biweekly, or placebo to the patients.

The newly released results have showed a statistically significant reduction in disease progression on the ADCOMS after 18 months of treatment in patients receiving the highest treatment dose of 10mg/kg biweekly as compared to placebo.

“We will discuss these very encouraging results with regulatory authorities to determine the best path forward.”

It was also found that BAN2401 was able to reduce the amount of amyloid accumulated in the brain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, BAN2401 showed an acceptable tolerability profile during the 18 months of study drug administration.

Eisai Neurology Business Group chief clinical officer and chief medical officer Lynn Kramer said: “This is the first late-stage anti-amyloid antibody study to successfully achieve statistically significant results at 18 months, further validating the amyloid hypothesis.

“We will discuss these very encouraging results with regulatory authorities to determine the best path forward.”

BAN2401 is a humanised monoclonal antibody for AD that is currently being developed by Eisai and BioArctic under a strategic research alliance.